Compound class:
Synthetic organic
Comment: Compound 19 is one of two potential lead SARS-CoV-2 antivirals from the same discovery effort [2]. Both compounds inhibit SARS-CoV-2 3CL protease (Mpro). Compound 21 [PMID: 34408808] is the other lead.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Compound 19 inhibits SARS-CoV-2 replication with an EC50 of 175 nM, and reduces plaque formation in Vero E6 cells with an EC50 of 80 nM [2]. In Vero E6 infection assays remdesivir's EC50 is reported in the 0.7-2.1 μM range [1]. Compound 19 has favourable aqueous solubility and low cytotoxicity. |
Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|